A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions
- 19 March 2025
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 997, 177535
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82273958)
- Jilin Provincial Science and Technology Department (20230204063YY, 20240404034ZP)
- Science and Technology Development Fund (0053-2021-AGJ)
- Guangdong Provincial Key Laboratory of Construction Foundation (2023B1212060022)
- Guangdong Provincial Natural Science Foundation (2024A1515011452, 2023A1515012521)
- Guangzhou Municipal Science and Technology Project (2022A0505020024)
- Traditional Chinese Medicine Bureau of Guangdong Province (20231079)
- Basic and Applied Basic Research Foundation of Guangdong Province
This publication has 38 references indexed in Scilit:
- Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer ImmunotherapyJournal of Medicinal Chemistry, 2023
- Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer ImmunotherapyJournal of Medicinal Chemistry, 2022
- Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic AgentsJournal of Medicinal Chemistry, 2021
- Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironmentInternational Immunopharmacology, 2020
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteersInvestigational New Drugs, 2018
- Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype SelectivityCell, 2017
- Potential Therapeutic Applications of Adenosine A2AReceptor Ligands and Opportunities for A2AReceptor ImagingMedicinal Research Reviews, 2017
- Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failureToxicology and Applied Pharmacology, 2017
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune ResponsesCancer Cell, 2016
- Adenosine mediated desensitization of cAMP signaling enhances T‐cell responsesEuropean Journal of Immunology, 2010